Is There a Big Opportunity for Amarin Investors?
Investor interest in biopharma company Amarin (NAS: AMRN) mounted this summer as the company gained approval from the Food and Drug Administration for its triglyceride-lowering drug, Vascepa. In an effort to help investors examine both the bull and bear cases for this stock, we've put together a brand new premium research report on Amarin that examines the company's market opportunity, biggest threats, and reasons to both buy and sell today.
In the following video, Austin Smith talks with health care analyst Max Macaluso about why this drug has garnered so much attention, what Vascepa actually does, and the competition that Amarin could soon face once this new medication reaches patients.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of Vascepa is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article Is There a Big Opportunity for Amarin Investors? originally appeared on Fool.com.Austin Smith has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.